Aptevo Therapeutics
APVO
11 hedge funds and large institutions have $191K invested in Aptevo Therapeutics in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
10% more funds holding
Funds holding: 10 → 11 (+1)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.71% less ownership
Funds ownership: 0.83% → 0.12% (-0.71%)
73% less capital invested
Capital invested by funds: $717K → $191K (-$526K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$401K |
| 2 |
Citigroup
New York
|
+$65.5K |
| 3 |
TCM
Tradewinds Capital Management
Bellingham,
Washington
|
+$309 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$285 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$166 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$435K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$191K |
| 3 |
VF
Virtu Financial
New York
|
-$56K |
| 4 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$14.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.45K |
APVO Hedge Fund Activity: Q4 2025 in Review
11 of the 8,237 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2025, worth a combined $191K — down 73% from $717K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new APVO positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $401K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $435K sold.
- 11 institutional investors held Aptevo Therapeutics (APVO) as of Q4 2025, up from 10 in Q3 2025.
- Funds reported $191K of Aptevo Therapeutics stock for Q4 2025, down 73% quarter-over-quarter.
- 5 funds opened new Aptevo Therapeutics positions in Q4 2025 and 4 closed out, a net change of +1 holder.
- The largest Aptevo Therapeutics buyer in Q4 2025 was Vanguard Group, an estimated $401K added.
- The largest Aptevo Therapeutics seller in Q4 2025 was Point72 Asset Management, an estimated $435K sold.
Based on aggregated 13F filings for Q4 2025.